Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity

J Clin Immunol. 2010 Mar;30(2):221-5. doi: 10.1007/s10875-009-9365-x. Epub 2010 Jan 28.

Abstract

Objective: To investigate the role of interleukin-17A (IL-17A) and Th17 cell in the pathogenesis of systemic lupus erythematosus (SLE), we studied the plasma IL-17A and the expression of Th17 cell transcription factor RORgammat in Chinese new-onset SLE patients.

Methods: Sixty SLE patients aged between 18 and 40 years and 56 age-matched healthy volunteers were involved in the study. Enzyme-linked immunosorbent assay was used to measure plasma IL-17A level, and rea1-time fluorescent quantitative polymerase chain reaction was used to measure RORgammat mRNA.

Results: The results showed that both IL-17A level and RORgammat mRNA in SLE patients were higher than that of controls. Correlation analysis indicated that plasma IL-17A level was positively correlated with Systemic Lupus Erythematosus Disease Activity Index, not with RORgammat mRNA.

Conclusion: We concluded that IL-17A might play a role in the pathogenesis of SLE and associated with disease activity. RORgammat-determined Th17 cell might be involved with increased IL-17A in SLE but not exclusively the unique source.

MeSH terms

  • Adolescent
  • Adult
  • Disease Progression
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Interleukin-17 / blood*
  • Lupus Erythematosus, Systemic / blood
  • Lupus Erythematosus, Systemic / immunology*
  • Lupus Erythematosus, Systemic / physiopathology
  • Male
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / biosynthesis*
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / genetics
  • Severity of Illness Index
  • T-Lymphocytes, Helper-Inducer / immunology
  • T-Lymphocytes, Helper-Inducer / metabolism*
  • T-Lymphocytes, Helper-Inducer / pathology

Substances

  • Interleukin-17
  • Nuclear Receptor Subfamily 1, Group F, Member 3